medigraphic.com
ISSN 0210-5187 (Digital)

2003, Número 3

<< Anterior Siguiente >>

Med Cutan Iber Lat Am 2003; 31 (3)


Enfermedad de Behçet

Londoño GAM, Hernández NDL

Idioma: Español
Referencias bibliográficas: 96
Paginas: 149-160
Archivo PDF: 332.91 Kb.


RESUMEN

La enfermedad de Behçet (EB) es un desorden complejo, caracterizado por aftas orales, erupción en piel, artritis, manifestaciones oculares como uveitis, vasculitis y en algunos casos afección de sistema nervioso y grandes vasos.
Son múltiples las teorías sobre su etiopatogenia, entre las que se resaltan la presencia del HLA-B51, agentes infecciosos, disregulación inmune, daño endotelial, entre otros. Se piensa que algunos agentes infecciosos pueden disparar una respuesta por parte de las células mononucleraes y endoteliales, que en un individuo susceptible por la presencia del HLA-B51, llevaría como paso final a la generación de una respuesta inflamatoria y finalmente la vasculitis.
Los tratamientos son tan variados, como las manifestaciones clínicas, incluyen colchicina, talidomida, esteroides y agentes inmunosupresores, según la severidad del compromiso, y se requiere de un grupo interdisciplinario para llegar a un adecuado control de la enfermedad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Schreiner DT, Jorizzo JL. Behcet’s disease and complex aphthosis. Dermatol Clin 1987; 5:760-78.

  2. Ghate JV, Jorizzo JL. Behcet’s disease and complex aphthosis. J Am Acad Dermatol 1999; 40:1-18.

  3. O’Duffy JD, Goldstein NP. Neurologic involvement in seven patients with Behcet’s disease. Am J Med 1976; 61:17-8.

  4. Yazici H, Yurdakul S, Hamuyudan V. Behçet´s disease. Curren Opinion in Rheumatology 2001, 13:18-22.

  5. Bang D. clinical spectrum of Behçet´s disease. J Dermatol. 2001; 28:610-3.

  6. Jacyk WK. Behcet’s disease in South African blacks: report of five cases. J Am Acad Dermatol 1994; 30:869-73.

  7. Dundar SV, Gencalp U, Simsek H. Familial cases of Behcet’s disease. Br J Dermatol 1985; 113:319-21.

  8. Goker B, Goker H. current therapy for Behçet disease. Am J Ther. 2002; 9:465-70.

  9. Monder MA. The multiple faces of Behçet´s disease and its aetiological factors. J Eur Acad Dermatol Venereol. 2001; 15: 126-36.

  10. Meador R, Ehrlich G, Von Feldt JM. Behçet´s disease: immunopathologic and therapeutic aspects. Curr Rheumatol Rep. 2002;4:47-54

  11. Gul A. Behçet´s disease: an update on the pathogenesis. Clin Exp Rheumatol. 2001; 19:6-12.

  12. Poon W, Verity Dh, Larkin GL, Graham EM, Stanford MR. Behçet´s disease in patients of west African and Afro-Caribbean origin. Br J Ophthalmol. 2003; 87:876-8.

  13. Jorizzo JL. Behcet’s disease: an update based on the 1985 international conference in London. Arch Dermatol 1986; 122:556-8.

  14. Prieto J, Suarez J, Civeria P. Acyclovir and Behcet’s disease [letter]. Ann Intern Med 1984; 101:565-6.

  15. Mizushima Y, Matsuda T, Hoshi K, Ohno S. Induction of Behcet’s disease symptoms following dental treatment and streptococcal antigen skin test. J Rheumatol 1988; 15:1029-30.

  16. Kaneko F, Takahashi Y, Muramatsu R, Miura Y. Immunological studies on aphthous ulcer and erythema nodosum-like eruptions in Behcet’s disease. Br J Dermatol 1985; 113:303-12.

  17. Sakane T, Suzuki N, Ueda Y, Takada S, Murakawa Y, Hoshino T, Niwa Y, Tsunematsu. T. Analysis of interleukin-2 activity in patients with Behcet’s disease. Arthritis Rheum 1986; 29:371-8.

  18. Dinarello CA. Interleukin-1 and the pathogenesis of the acute phase response. N Engl J Med 1984; 311:1413-8.

  19. Karasneth J, Hajeer AH, Barrett J, Ollier WE, Thornhill M, Gul A. Association of specific interleukin 1 gene cluster polymorphisms with increased susceptibility for Behçet´s disease. Rheumatology. 2003; 42:860-4.

  20. Frassanito MA, Dammacco R, Cafforio P, Dammacco F. Th1 polarization of the immune response in Behçet´s disease: a putative pathogenetic role of the interleukin-12. Arthritis Rheum 1999, 42:1967-74.

  21. Valesini G, Pivetti-Pezzi P, Mastrandrea F, Moncada A, Cuomo M, Natali PG. Evaluation of T cell subsets in Behcet’s syndrome using anti-T cell monoclonal antibodies. Clin Exp Immunol 1985; 60:55-60.

  22. Kaneko F, Takahashi Y, Muramatsu R, Adachi K, Miura Y, Nakane A, Minagawa T. Natural killer cell numbers and function in peripheral lymphocytes in Behcet’s disease. Br J Dermatol 1985; 113:313-8.

  23. Suzuki N, Sakane T, Ueda Y, Tsunematsu T. Abnormal B cell function in patients with Behcet’s disease. Arthritis Rheum 1986; 29:212-9.

  24. Sancak B, Onder M, Oztas MO, Bukan N, Gurer MA. Nitric oxide levels in Behcet´s disease. J Eur Acad Dermatol Venereol. 2003; 17:7-9.

  25. Koçak M, Erbast A, Ozturk G, Eksioglu M. Behçet´s disease and nitric oxide production. Int J Dermatol. 2003; 42: 244-48.

  26. Batioglu F, Atmaca LS, Karabulut HG, Beyza Sayin D. Factor V Leiden and prothrombin gene G 20210A mutations in ocular Behçet´s disease. Acta Ophthalmol Scand. 2003; 81: 283-5.

  27. Spencer William. Inflamatory diseases and conditions of the eye: Behçet´s disease. En: Ophthalmic Pathology an atlas and textbook. 4th edition. CD-ROM Edition. 1994. Cap 10.

  28. Nussenblat R, Whitcup S, Palestine A. Behçet disease. En: Uveitis Fundamentals and clinical practice.2 ed. Ed Mosby.1996. Capitulo 25. pags 334-353.

  29. Inoue C, Itoh R, Kawa Y, Mizoguchi M. Pathogenesis of mucocutaneous lesions in Behcet’s disease. J Dermatol 1994; 21:474-80.

  30. Cappele O, Nicolas J, Bottet P, Bensadoun H. Urological manifestations of Behçet´s disease. Prog urol. 2003; 13: 329-31.

  31. Jorizzo JL, Taylor RS, Schmalstieg FC, et al. Complex aphthosis: A forme fruste of Behcet’s syndrome? J Am Acad Dermatol 1985; 13:80-4.

  32. McCarty MA, Garton RA, Jorizzo JL. Complex aphthosis and Behçet´s disease. Dermatol Clin. 2003; 21: 41-8, vi.

  33. Diri E, Mat C, Hamuryudan V, et al. Papulopustular lesions are seen more frequently in patients with Behçet´s syndrome who have arthritis: a controlled and masked study. Ann Rheum Dis 2001; 60:1074-76.

  34. Balanova M, Calamia K, Perniciario C, O´Duffy J.D. A study of the cutaneous manifestations of Behçet´s disease in patients of the United States, J Am Acad Dermatol 1999; 41: 540-5.

  35. Dogan B, Taskapan O, Harmanyeri Y. prevalence or pathergy test positivity in Behçet´s disease in Turkey. J Eur Acad Dermatol Venereaol. 2003; 17: 228-9.

  36. Poole, T, Graham,E. Ocular manifestations of rheumatologic disorders ( Ocular manifestations of systemic disease ]. Current Opinion Ophthalmol 1999; 10: 458-463.

  37. Godfrey William. Behçet disease. En: Duane´s Ophthalmology Fundations of clinical ophthalmology. CD-Rom edition 1996. Clinical vol4 cap 40.

  38. Sakamoto M, Akazawa K, Nishioka Y, Sanui H, et al. Prognostic factors of vision in patients with Behcet’s disease. Ophthalmology 1995; 102:317-21.

  39. Matsuo T, Itami M, Nakagawa H, Nagayama M. The incidence and pathology of conjuntival ulceration in Behcet’s Syndrome. BJO 2002; 86: 140-3.

  40. Zamir E, Bodaghi B, Tugal-Tukun I, See RF, Charlotte F, Wang RE, Wechsler B, LeHuang P, Anteby I, Rao NA. Conjuntival ulcers in Behçet´s disease. Ophthalmology. 2003;110: 1137-41.

  41. Tohme A, Haddad F, Ghayad E. Neurologic manifestations in Behcet’s disease. 16 cases in a cohort of 110 patients. Ann Med Interne 1997; 148:118-24.

  42. Brama I, Fainaru M. Inner ear involvement in Behcet’s disease. Arch Otolaryngol 1980; 106:215-7.

  43. Ozturk MA, Ertenli I, Kiraz S, C Haznedaroglu I, Celik I, Kirazli S, calguneri M. Plasminogen activator inhibitor-1 as a link between pathological fibrinolysis and arthritis of Behçet´s disease. Rheumatol Int. 2003. May 15.

  44. Bayraktar Y, Balkanci F, Bayraktar M, Calguneri M. Budd-Chiari syndrome: a common complication of Behcet’s disease. Am J Gastroenterol 1997; 92:858-62.

  45. Bowles CA, Nelson AM, Hammill SC, O’Duffy JD. Cardiac involvement in Behcet’s disease. Arthritis Rheum 1985;28:345-8.

  46. Hattori S, Kawana S. Behcetçs syndrome associated with acute myocardial infaction. J Nippon Med Sch. 2003; 70: 49-52.

  47. Huong DL, Wechsler B, Papo T, de Zuttere D, et al. Endomyocardial fibrosis in Behcet’s disease. Ann Rheum Dis 1997; 56:205-8. 157 Bibliografía Med Cutan Iber Lat Am 2003; 31(3): 149-160 16 Londoño García A.Mª., et al. Enfermedad de Behçet

  48. Tursen U, Ulabas B, Irfan Kaya T, Pekdemirt H, Ikizoglu G. Cardiac Complications in Behçet´s disease. Clin Exp Dermatol. 2002; 27: 651-3.

  49. Hamza M. Large artery involvement in Behcet’s disease. J Rheumatol 1987;14:554-9.

  50. Roguin A, Edoute Y, Milo S, Shtiwi S, Markiewicz W, Reisner SA. A fatal case of Behcet’s disease associated with multiple cardiovascular lesions. Int J Cardiol 1997; 59:267-73.

  51. Erkan F, Kiyan E, Tunaci A. Pulmonary complications of Behçet´s disease. Clin Chest Med. 2002; 23:493-503.

  52. Olsson PJ, Gaffney E, Alexander RW, et al. Proliferative glomerulonephritis with crescent formation in Behcet’s syndrome. Arch Intern Med 1980; 140:713-4.

  53. Cengiz N, Karaoglanoglu M, Cengiz K, Akpulat T. Behçet´s disease and focal segmental glomerulosclerosis. Clin Nephrol. 2003; 59:234-5.

  54. Hemmen T, Perez-Canto A, Distler A, Offermann G, Braun J. IgA nephropathy in a patient with Behcet’s syndrome: case report and review of literature. Br J Rheumatol 1997; 36:696-9.

  55. Zahiri K, Hachim K, zamd A, Fatihi E, Benghanem MG, Ramdani B, Sqalli S, Zaid D. renal involvement in Behçet´s disease. About six cases. Rev Med Interne. 2003; 24:4-10.

  56. Kone-Paut I, Yurdakul S, Bahabri SA, Shafae N, Ozen S, Ozdogan H, Bernard JL. Clinical features of Behçet´s disease in children: An international collaborative study of 86 cases. J Pediatr 1998; 132: 721-5.

  57. Kone-Paut I, Geisler I, Wechsler B, Ozen S, Ozdogan H, Rozenbaum M, Touitou. Familial aggregation in Behçet´s syndrome: high frequency in siblings and parents of pediatric probands. J Pediatr 1999; 135:89-93.

  58. Guezelian G, Norton ME. Behcet’s syndrome associated with intrauterine growth restriction: a case report and review of the literature. J Perinatol 1997; 17:318-20.

  59. Jorizzo JL, Abernethy JL, White WL, Manglesdorf HC, et al. Mucocutaneous criteria for the diagnosis of Behcet’s disease: an analysis of clinicopathologic data from multiple international centers. J Am Acad Dermatol 1995; 32:968-76.

  60. Alpsoy E, Uzun S, Alpaslan M, Memisoglu HR, Basarant E. Histological and immunofluorescence findings of non-follicular papulopustular lesions in patients with Behçet’s disease. J Eur Acad Dermatol Venereol. 2003; 17:521-524.

  61. Senturk N, Yildiz, L, Sullu Y, Kandemir B, Turanli AY. Expresión of bcl-2 protein in active skin lesions of Behçet´s disease. Int J Dermatol. 2001; 40: 747-50.

  62. Jorizzo JL, Hudson RD, Schmalstieg FC, Daniels JC, Apisarnthanarax P, Henry JC, Gonzalez EB, Ichikawa Y, Cavallo T. Behcet’s syndrome: immune regulation, circulating immune complexes, neutrophil migration, and colchicine therapy. J Am Acad Dermatol 1984; 10:205-14.

  63. Vidaller Palacin A, Rober Olalla J, Sanuy Jimenez B, Rufi Rigau G, Folch Civit J, Charte Gonzalez A. Behçet´s disease therapy review. An Med Interna. 2002; 19:594-8.

  64. Miyachi Y, Taniguchi S, Ozaki M, Horio T. Colchicine in the treatment of cutaneous manifestations of Behcet’s disease. Br J Dermatol 1981; 104:67-9.

  65. Wechsler B. colchicines and Behçet´s disease: an efficacious treatment finally recognized. Rev Med Interne. 2002; 23: 355-6.

  66. Fontes V, Machet L, Huttenberger B, Lorette G, Vaillant L. recurrent aphthous stomatitis: treatment with colchicine. An open trial of 54 cases. Ann Dermatol Venereol. 2002; 129:1365-9.

  67. Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Hamuryudan V, Uysal O, et al. A double-blind trial of colchicine in Behçet´s syndrome. Arthritis Rheum. 2001; 44:2686-92.

  68. Sharquie K. Suppression of Behcet’s disease with dapsone. Br J Dermatol 1984; 110:493-4.

  69. Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behçet´s disease: a double-blind, placebo-controlled crossover study. J Dermatol. 2002; 29:267-79.

  70. Gardner-Medwin JM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet’s disease: use of neurophysiologic studies to detect thalidomide neuropathy. Ann Rheum Dis 1994; 53:828-32.

  71. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, Zwingenberger K, Yazici H. Thalidomide in the treatment of the mucocutaneous lesions of Behcet’s syndrome: a randomized double-blinded, placebo controlled trial. Ann Intern Med 1998; 128:443-50.

  72. Shek LP, Lim DL. Thalidomide in Behçet´s disease. Biomed Pharmacother. 2002; 56: 31-5.

  73. Revuz J, Guillaume J-C, Janier M. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol 1990; 126:923-7.

  74. Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, Fox L, Chernoff M, Wu AW, MacPhail LA, Vasquez GJ, Wohl DA. Thalidomide for the treatment of oral aphthous ulcers in patients with HIV. National Institute of Allergy and Infectious diseases AIDS clinical trials group. N Engl J Med 1997; 336:1487-93.

  75. Brik R, Shamali H, bergman R. Successful thalidomide treatment of severe infantile Behçet disease. Pediatr Dermatol. 2001; 18: 143-5.

  76. Jorizzo JL, White WL, Wise CM, Zanolli MD, Sherertz EF. Low-dose weekly methotrexate for unusual vascular reactions: cutaneous polyarteritis nodosa and Behcet’s disease. J Am Acad Dermatol 1991; 24:973-8.

  77. Alpsoy E, Yilmaz E, Basaran E. Interferon therapy for Behcet’s disease. J Am Acad Dermatol 1994; 31:617-9.

  78. Hamuryudan V, Moral F, Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Direskeneli H, Akoglu T, Yazici H. . Systemic interferon alpha 2b treatment in Behcet’s syndrome. J Rheumatol 1994; 21:1098-100.

  79. Calguneri M, Ozturk MA, Ertenli I, Kiraz S, Apras S, Ozbalkan Z. effects of interferon alpha treatment on the clinical course of refractory Behçet´s disease: an open study. Ann Rheum Dis. 2003; 62: 492-3.

  80. Wechsler B, Du-Boutin LT. Interferons and Behçet is disease. Rev Med Interne. 2002; 23: 495s-499s.

  81. Hamuryudan V, Ozyazgan Y, Hizli N, Mat C, Yurdakul S, Tuzun Y, Senocak M, Yazici H. Azathioprine in Behcet’s syndrome: effects on long-term prognosis. Arthritis Rheum 1997; 40:769-74.

  82. Hamuryudan V, Ozyazgan Y, Fresko Y, Mat C, Yurdakul S, Yazici H. Interferon alfa combined with azathioprine for the uveitis of Behçet´s disease: an open study. Isr Med Assoc J. 2002; 4: s928-30.

  83. Nussenblatt RB, Palestine AG, Chan C. Effectiveness of cyclosporine therapy for Behcet’s disease. Arthritis Rheum 1985; 28:671-9.

  84. Avci O, Gurler N, Gune AT. Efficacy of cyclosporine on mucocutaneous manifestations of Behcet’s disease. J Am Acad Dermatol 1997; 36:796-7.

  85. Whitcup SM, Salvo EC Jr, Nussenblatt RB. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behcet’s disease. Am J Ophthalmol 1994; 118:39-45.

  86. Ishioka M, Ohno S, Nakamura S. FK506 treatment of noninfectious uveitis. Am J Ophthalmol 1994; 118:723-9.

  87. Hisamatsu T, Kishikawa H, Fukuya H, Matsuoka K, Mizuno Y, Nishida J. Combination therapy including pentoxifylline for entero-Behcet´s disease. Bull Tokyo Dent Coll. 2001; 42:169-76 (abstract).

  88. Oliveira-Soares R, Freitas JP, Sousa Ramalho P, Guerra Rodrigo F. Treatment with pentoxifylline in Behçet´s disease. J eur Acad dermatol Venereol. 2002; 16: 181-2.

  89. Aeberli D, Oertle S, Mauron H, Reichenbach S, Jordi B, Villiger PM. Inhibition of the TNF-pathway: use of infliximab and etarnecept as remission-inducing agents in cases of therapy resistan chronic inflammatory disorder. Swiss Med Wkly. 2002; 132:414-22 (abstract].

  90. Goossens PH, Verburg RJ, Breedveldt FC. Remission of Behçet´s syndrome with necrosis factor alpha blocking therapy. Ann Rheum Dis. 2001; 60:637

  91. Sfikaki PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of Infliximab on Sight-threatening panuveitis in Behçet´s disease. Lancet. 2001; 358: 295-6.

  92. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behçet´s syndrome with chimeric tumour necrosis factor alpha antibody. Gut. 2001; 49: 725-8.

  93. Sfikakis PP. Behçet´s disease: a new target for anti.tumour necrosis factor treatment. Ann Rheum Dis. 2002; 61: ii51-3.

  94. Andreu M, Ramanoelina J, Fajnkuchen F, Mouthon L, Cohen P, Laroche L, Guillevin L. Treatment of severe Behçet´s disease with anti-TNF alpha: infliximab. A case report. Ann Med Interne. 2002; 153:414-5.

  95. Sheinberg MA. Treatment of recurrent oral aphthous ulcers with etarnecept. Clin Exp Rheumatol. 2002; 20:733-4.

  96. Licata G, Pinto A, Tuttolomondo A, Banco A, Ciccia F, Ferrante A, Triolo G. Anti-tumor necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis inpaptient with Behçet´s syndrome. Ann Rheum Dis. 2003; 62:280-1.




2020     |     www.medigraphic.com